Personalized prostate cancer screening among men with high risk genetic predisposition- study protocol for a prospective cohort study

• Published in: BMC cancer 2014-07, Vol.14 (1), p.528-528, Article 528
• Main Authors: Margel, David, Benjaminov, Ofer, Ozalvo, Rachel, Shavit Grievink, Liat, Kedar, Inbal, Yerushalmi, Rinat, Ben-Aharon, Irit, Neiman, Victoria, Yossepowitch, Ofer, Kedar, Daniel, Levy, Zohar, Shohat, Mordechai, Brenner, Baruch, Baniel, Jack, Rosenbaum, Eli
• Format: Article
• Language: English
• Subjects: Adult; Aged; Biological Specimen Banks - standards; BRCA1 Protein - genetics; BRCA2 Protein - genetics; Breast cancer; Early Detection of Cancer - methods; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Male; Middle Aged; Mortality; Mutation; Ovarian cancer; Precision Medicine; Prospective Studies; Prostate cancer; Prostate-Specific Antigen - blood; Prostatic Neoplasms - diagnosis; Prostatic Neoplasms - genetics; Prostatic Neoplasms - pathology; Study Protocol
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/1471-2407-14-528

Prostate cancer screening among the general population is highly debatable. Nevertheless, screening among high-risk groups is appealing. Prior data suggests that men carrying mutations in the BRCA1& 2 genes may be at increased risk of developing prostate cancer. Additionally, they appear to develop prostate cancer at a younger age and with a more aggressive course. However, prior studies did not systematically perform prostate biopsies and thus cannot determine the true prevalence of prostate cancer in this population. This will be a prospective diagnostic trial of screening for prostate cancer among men with genetic predisposition. The target population is males (40-70 year old) carrying a BRCA1 and/or BRCA2 germ line mutation. They will be identified via our Genetic counseling unit. All men after signing an informed consent will undergo the following tests: PSA, free to total PSA, MRI of prostate and prostate biopsy. The primary endpoint will be to estimate the prevalence, stage and grade of prostate cancer in this population. Additionally, the study aims to estimate the impact of these germ line mutations on benign prostatic hyperplasia. Furthermore, this study aims to create a bio-bank of tissue, urine and serum of this unique cohort for future investigations. Finally, this study will identify an inception cohort for future interventional studies of primary and secondary prevention. The proposed research is highly translational and focuses not only on the clinical results, but on the future specimens that will be used to advance our understanding of prostate cancer patho-physiology. Most importantly, these high-risk germ-line mutation carriers are ideal candidates for primary and secondary prevention initiatives. ClinicalTrials.gov: NCT02053805.